Stocktoria
Sol-Gel Technologies Ltd. SLGL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-02-01
Sol-Gel Technologies Ltd. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -38.9% | -104.1% | -1885.8% | -418.3% | 9.5% |
| Net margin | -31.6% | -91.7% | -1752.8% | -384.3% | 10.3% |
| FCF margin | 1.4% | -120.4% | -1149.5% | -248.6% | -25.1% |
| Return on assets | -20.5% | -29.5% | -60.1% | -32.0% | 4.7% |
| Return on equity | -26.9% | -36.7% | -70.5% | -35.4% | 5.8% |
| Current ratio | 4.37 | 5.92 | 9.10 | 12.93 | 4.88 |
| Revenue growth | 68.0% | 642.5% | -60.0% | -87.6% | 256.5% |
Source: SEC EDGAR filings · CIK 0001684693 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.